Immunology Phase 3 Readout Calendar
Industry-sponsored immunology trials with primary completion in the next 12 months or last 12 months.
Data last updated July 17, 2026 · source: ClinicalTrials.gov
All areas OncologyImmunologyMetabolicCNSCardiovascularInfectious DiseaseRespiratoryRare DiseaseOphthalmologyDermatologyMusculoskeletalRenalPain
52
Next 6 months
95
Next 12 months
30
Results posted
355
Phase 3 Immunology
What you can answer with this page
A confidence-graded calendar of every industry Phase 3 immunology trial reading out in the next 12 months — with a per-row staleness flag so you know which completion dates are still credible.
What immunology trials are reading out soon?
The "upcoming" section shows industry-sponsored Phase 3 immunology trials with primary completion ahead, soonest first, each graded by how credible that date is.
Which immunology trials have already read out?
The "recently read out" section shows Phase 3 immunology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline.
How are these readout dates sourced?
Every date is the ClinicalTrials.gov primary completion date — the only public, structured signal. We grade each by whether it is actual or sponsor-estimated, and by how recently the trial record was updated.
Where can I see readouts for other therapeutic areas?
The full cross-area calendar is on the main readout calendar; this page is the Immunology slice of it.
Recently read-out results are free; the upcoming calendar shows a free preview. See the full cross-area calendar → or the Immunology landscape →
Recently read out & awaiting topline — Immunology
· 27Phase 3 immunology trials whose primary endpoint completed in the last 12 months — results posted, or completed and awaiting topline. Most recent first.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| UCB Biopharma SRL | A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque Psoriasis Asset: Certolizumab pegol | Moderate Chronic Plaque Psoriasis +2 | Active Not Recruiting | Q2 2026 2026-04-09 | Completed · awaiting
Updated 3mo ago
| NCT04123795 |
| Eli Lilly and Company | A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3) Asset: Mirikizumab | Ulcerative Colitis | Active Not Recruiting | Q1 2026 2026-03-04 | Completed · awaiting
Updated 3mo ago
| NCT03519945 |
| Celltrion | A Study to Compare Efficacy and Safety of CT-P55 and Cosentyx in Patients With Moderate to Severe Psoriasis Asset: CT-P55 | Plaque Psoriasis | Active Not Recruiting | Q1 2026 2026-02-18 | Completed · awaiting
Updated 5mo ago
| NCT06630559 |
| UCB Biopharma SRL | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis Asset: Bimekizumab | Psoriatic Arthritis | Completed | Q1 2026 2026-02-06 | Completed · awaiting
Updated 3mo ago
| NCT06624228 |
| Sun Pharmaceutical Industries Limi… | A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. Asset: Tildrakizumab 100 mg | Moderate to Severe Genital Psoriasis | Active Not Recruiting | Q1 2026 2026-01-21 | Completed · awaiting
Updated 4mo ago
| NCT06611163 |
| Eli Lilly and Company | A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis Asset: Lebrikizumab | Atopic Dermatitis +1 | Active Not Recruiting | Q1 2026 2026-01-14 | Completed · awaiting
Updated 6mo ago
| NCT05559359 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight Asset: Ixekizumab | Psoriasis +1 | Completed | Q1 2026 2026-01-08 | Completed · awaiting
Updated 6mo ago
| NCT06588283 |
| Alexion Pharmaceuticals, Inc. | Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) Asset: Ravulizumab | Immunoglobulin A Nephropathy +1 | Active Not Recruiting | Q1 2026 2026-01-05 | Completed · awaiting
Updated 3mo ago
| NCT06291376 |
| Alexion Pharmaceuticals, Inc. | Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Eculizumab in Chinese Adults With gMG Asset: Eculizumab | Generalized Myasthenia Gravis (gMG) +1 | Completed | Q4 2025 2025-12-29 | Completed · awaiting
Updated 6mo ago
| NCT06764160 |
| Pfizer | Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis Asset: Abrocitinib 100 mg | Dermatitis, Atopic | Completed | Q4 2025 2025-12-22 | Completed · awaiting
Updated 6mo ago
| NCT03422822 |
| Amgen | A Study to Assess the Efficacy and Safety of Apremilast in Japanese Pediatric Participants With Moderate to Severe Plaque Psoriasis Asset: Apremilast | Plaque Psoriasis | Active Not Recruiting | Q4 2025 2025-11-20 | Completed · awaiting
Updated 7mo ago
| NCT05565560 |
| Eli Lilly and Company | Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight Asset: Ixekizumab | Psoriatic Arthritis +1 | Completed | Q4 2025 2025-11-18 | Completed · awaiting
Updated 6mo ago
| NCT06588296 |
| Janssen Research & Development, LLC | A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis Asset: JNJ-77242113 | Plaque Psoriasis | Active Not Recruiting | Q4 2025 2025-11-17 | Completed · awaiting
Updated 3mo ago
| NCT06934226 |
| Amgen | A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis Asset: Apremilast | Psoriasis | Completed | Q4 2025 2025-10-30 | Completed · awaiting
Updated 7mo ago
| NCT04175613 |
| Takeda | A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis Asset: TAK-279 | Generalized Pustular Psoriasis +1 | Active Not Recruiting | Q4 2025 2025-10-15 | Completed · awaiting
Updated 8mo ago
| NCT06323356 |
| Celgene | To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis Asset: Ozanimod | Colitis, Ulcerative | Completed | Q3 2025 2025-09-30 | Completed · awaiting
Updated 9mo ago
| NCT03915769 |
| Sunshine Guojian Pharmaceutical (S… | Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis Asset: 611 | Dermatitis, Atopic | Completed | Q3 2025 2025-09-26 | Completed · awaiting
Updated 6mo ago
| NCT06173284 |
| Eli Lilly and Company | A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis Asset: Placebo | Atopic Dermatitis | Active Not Recruiting | Q3 2025 2025-09-25 | Completed · awaiting
Updated 9mo ago
| NCT06280716 |
| Alumis Inc | A Study in Patients With Moderate to Severe Plaque Psoriasis to Evaluate the Efficacy and Safety of ESK-001 Asset: Envudeucitinib | Plaque Psoriasis | Completed | Q3 2025 2025-09-23 | Completed · awaiting
Updated 3mo ago
| NCT06588738 |
| Alumis Inc | A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis Asset: Envudeucitinib | Plaque Psoriasis | Completed | Q3 2025 2025-09-19 | Completed · awaiting
Updated 3mo ago
| NCT06586112 |
| Novartis Pharmaceuticals | Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients Asset: Placebo | IgA Nephropathy | Completed | Q3 2025 2025-09-19 | Completed · awaiting
Updated 7mo ago
| NCT04578834 |
| Novartis Pharmaceuticals | Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. Asset: Remibrutinib | Chronic Spontaneous Urticaria | Active Not Recruiting | Q3 2025 2025-09-17 | Completed · awaiting
Updated 4mo ago
| NCT06042478 |
| Hoffmann-La Roche | A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus Asset: Obinutuzumab | Systemic Lupus Erythematosus | Active Not Recruiting | Q3 2025 2025-09-15 | Completed · awaiting
Updated 3mo ago
| NCT04963296 |
| Shanghai Chia Tai Tianqing Pharmac… | To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis Asset: TQH2722 injection | Atopic Dermatitis | Active Not Recruiting | Q3 2025 2025-09-11 | Completed · awaiting
Updated 3mo ago
| NCT06552520 |
| AstraZeneca | Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus Asset: Medi-546 | Systemic Lupus Erythematosus | Active Not Recruiting | Q3 2025 2025-08-22 | Completed · awaiting
Updated 3mo ago
| NCT04877691 |
| Lynk Pharmaceuticals Co., Ltd | A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis (COURAGE-RA) Asset: LNK01001 | Rheumatoid Arthritis | Active Not Recruiting | Q3 2025 2025-08-22 | Completed · awaiting
Updated 6mo ago
| NCT06276998 |
| Amgen | A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Asset: Rocatinlimab | Atopic Dermatitis | Completed | Q3 2025 2025-07-31 | Completed · awaiting
Updated 7mo ago
| NCT05633355 |
Upcoming immunology readouts — next 12 months
· 95Industry Phase 3 immunology trials with primary completion ahead, soonest first — confidence-graded by date type and CT.gov staleness.
| Sponsor | Trial / Asset | Indication | Status | Primary completion | Confidence | NCT |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb | Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis Asset: BMS-986165 | Psoriasis | Active Not Recruiting | Q3 2026 2026-07-25 (est.) | Estimated · aging
Updated 9mo ago
| NCT04036435 |
| UCB Biopharma SRL | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Asset: Bimekizumab | Hidradenitis Suppurativa | Active Not Recruiting | Q3 2026 2026-07-28 (est.) | Estimated · fresh
Updated 3mo ago
| NCT04901195 |
| AbbVie | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis Asset: Upadacitinib | Rheumatoid Arthritis | Active Not Recruiting | Q3 2026 2026-07 (est.) | Estimated · fresh
Updated 6mo ago
| NCT05814627 |
| Suzhou Suncadia Biopharmaceuticals… | The Efficacy and Safety of SHR-1314 in the Treatment of Pediatric Patients of Age 6 to <18 Years With Moderate to Severe Plaque Psoriasis Asset: SHR-1314 | Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis | Not Yet Recruiting | Q3 2026 2026-07 (est.) | Estimated · stale
Updated 17mo ago
| NCT06833307 |
| Merck Sharp & Dohme LLC | A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) Asset: Tulisokibart | Ulcerative Colitis | Active Not Recruiting | Q3 2026 2026-08-01 (est.) | Estimated · fresh
Updated 4mo ago
| NCT06052059 |
| Hoffmann-La Roche | A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis Asset: Afimkibart | Moderately to Severely Active Ulcerative Colitis | Recruiting | Q1 2027 2027-01-30 (est.) | Estimated · fresh
Updated 4mo ago
| NCT06588855 |
| Hoffmann-La Roche | A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis Asset: Afimkibart | Moderately to Severely Active Ulcerative Colitis | Active Not Recruiting | Q1 2027 2027-01-30 (est.) | Estimated · fresh
Updated 4mo ago
| NCT06589986 |
| Novartis Pharmaceuticals | Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1) Asset: Ianalumab | Systemic Lupus Erythematosus | Active Not Recruiting | Q1 2027 2027-03-24 (est.) | Estimated · fresh
Updated 4mo ago
| NCT05639114 |
| Novartis Pharmaceuticals | Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Asset: Ianalumab | Systemic Lupus Erythematosus | Active Not Recruiting | Q2 2027 2027-04-12 (est.) | Estimated · fresh
Updated 4mo ago
| NCT05624749 |
| Novartis Pharmaceuticals | Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis Asset: Ianalumab | Lupus Nephritis | Active Not Recruiting | Q2 2027 2027-06-22 (est.) | Estimated · fresh
Updated 4mo ago
| NCT05126277 |
Unlock 85 more immunology readouts · plus filters on the full calendar
About this calendar
Dates anchor on the ClinicalTrials.gov primary completion date — the only public, structured signal — and are graded by date type (actual vs sponsor-estimated) and how recently the record was updated. Sponsor-estimated dates can slip silently, so treat each as a current target rather than a guarantee. See the full readout calendar for all areas and filters.